Study for association with dermatological adverse event induced by molecular targeted drugs and profile of body weigh dispersion

Study for association with dermatological adverse event induced by molecular targeted drugs and profile of body weigh dispersion - Association with dermatological adverse event induced by molecular targeted drugs and profile of body weigh dispersion

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018948

Enrollment

Registered

2015-09-08

Start date

2014-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic renal cell cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. self agreement 2. ECOG-PS 0-2 3. renal cell carcinoma 4. patients received treatment of sorafenib, sunitinib, or axitinib

Exclusion criteria

Exclusion criteria: 1. hypersensitivity of sorafenib, sunitinib, or axitinib

Design outcomes

Primary

Measure	Time frame
Difference of loading ratio in each planter region before treatment of multiple-tyrosine kinase inhibitors and ideal loading ratio of them in Japanese	—

Secondary

Measure	Time frame
1. 2. 3.	—

Countries

Japan

Contacts

Public ContactKazuhiro Yamamoto

Kobe University Hospital Pharmacy

yamakz@med.kobe-u.ac.jp078-382-6659

Outcome results